Nitric Oxide Inhibits Hepatitis B Virus Replication in the Livers of Transgenic Mice by Guidotti, Luca G. et al.
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/2000/04/1247/06 $5.00
Volume 191, Number 7, April 3, 2000 1247–1252
http://www.jem.org/cgi/current/full/191/7/1247
 
Brief Deﬁnitive Report
 
1247
 
Nitric Oxide Inhibits Hepatitis B Virus Replication
in the Livers of Transgenic Mice
 
By Luca G. Guidotti, Heike McClary, Jacquelyn Moorhead Loudis,
 
 
 
and Francis V. Chisari
 
From the Department of Molecular and Experimental Medicine, The Scripps Research Institute, La 
Jolla, California 92037
 
Abstract
 
We have previously identified two antiviral cytokines (interferon [IFN]-
 
g
 
 and IFN-
 
a
 
/
 
b
 
) that
downregulate hepatitis B virus (HBV) replication in the liver of transgenic mice. The cytokine-
inducible downstream events that inhibit HBV replication have not been identified. One pos-
sible factor is nitric oxide (NO), a pleiotropic free radical with antiviral activity that is produced
in the liver by the inducible NO synthase (iNOS). To examine the role of NO in our model,
we crossed transgenic mice that replicate HBV with mice that lack a functional iNOS. Impor-
tantly, iNOS-deficient mice were almost completely resistant to the noncytopathic inhibitory
effect of HBV-specific cytotoxic T lymphocytes on viral replication, an effect that we have
shown previously to depend on the intrahepatic induction of IFN-
 
g
 
. Conversely, iNOS-defi-
cient mice were not resistant to the antiviral effect of IFN-
 
a
 
/
 
b
 
 induced by either polyinosinic-
polycytidylic acid complex or by lymphocytic choriomeningitis virus (LCMV) infection.
These results indicate that NO mediates the antiviral activity of IFN-
 
g
 
, whereas the antiviral
activity of IFN-
 
a
 
/
 
b
 
 is NO independent. We also compared the relative sensitivity of LCMV
to control by NO in these animals. Interestingly, LCMV replicated to higher levels in the liver
of iNOS-deficient mice than control mice, indicating that NO controls LCMV replication in
the liver, as well as HBV.
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Introduction
 
We have shown previously that hepatitis B virus (HBV)-
specific CTLs can abolish viral replication in the hepato-
cytes of HBV transgenic mice by noncytopathic mecha-
nisms that are mediated by cytokines such as IFN-
 
g
 
 (1–3).
In addition, we have shown that IFN-
 
a
 
/
 
b
 
 inhibits HBV
replication in these animals after polyinosinic-polycytidylic
acid complex (poly-I/C) injection (3) or during unrelated
hepatotropic virus infections, including lymphocytic chorio-
meningitis virus (LCMV [4]). Recent results obtained in
chimpanzees acutely infected with HBV indicate that simi-
lar cytokine-dependent noncytopathic antiviral events con-
tribute to viral clearance during HBV infection (5).
As IFN-
 
a
 
/
 
b
 
 and IFN-
 
g
 
 presumably do not represent the
final mediators in this system, downstream factors induced
by the cytokines such as RNase L, double-stranded RNA-
dependent protein kinase (6), and nitric oxide (NO) proba-
bly mediate their antiviral effects. In this study, we exam-
ined the role of NO as a potential candidate in this process.
NO is a highly unstable product of L-arginine metabolism
that exerts its functions in a paracrine and autocrine fashion
(7). NO is made by distinct categories of NO synthase
(iNOS) isoforms (7). The constitutive forms are present in
different cell types (including endothelial and neuronal
cells) and synthesize low amounts of NO (7). The induc-
ible forms are present in macrophages and hepatocytes and
synthesize high amounts of NO upon activation by cyto-
 
kines such as IFN-
 
g
 
, TNF-
 
a
 
, and IL-1
 
a
 
 (7). NO is a medi-
ator of several physiological functions, including vasodila-
tation, inhibition of platelet aggregation, and neuronal
communication (7).
 
It is well known that the inducible production of NO by
macrophages inhibits the growth of many pathogens, in-
cluding bacteria, fungi, and parasites (7). Similarly, NO in-
hibits herpes simplex virus, ectromelia virus, and vaccinia vi-
rus replication in vitro (7, 8). Thus, it is possible that NO
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may mediate the antiviral activity of IFN-
 
g
 
 and/or IFN-
 
a
 
/
 
b
 
in our system. To test this hypothesis, we crossed transgenic
mice that replicate HBV with mice that are genetically
iNOS-deficient, and we monitored the contribution of NO
to the antiviral effects of cytokines induced in the liver by
HBV-specific CTLs, poly-I/C, or LCMV infection in these
animals. In addition, we monitored the ability of NO to in-
hibit LCMV replication in these animals in order to com-
pare the relative sensitivity of HBV and LCMV to NO.
 
Materials and Methods
 
Mice. 
 
The HBV transgenic mouse lineage 1.3.46 (inbred
B10.D2) used in this study (official designation, Tg[HBV 1.3 ge-
nome]Chi46) has been described previously (9). These mice repli-
cate HBV at high levels in the liver without any evidence of cyto-
pathology. Lineage 1.3.46 was crossed with mice that lack a
functional iNOS allele (iNOS
 
2
 
/
 
2 
 
[10]). The knockout mice were
provided by Drs. John Mudgett (Merck Research Laboratories,
Rahway, NJ), and John MacMicking and Carl Nathan (Cornell
University Medical College, New York, NY). Heterozygous
mice from lineage 1.3.46 were crossed with iNOS
 
2
 
/
 
2
 
 mice to
yield progeny that were screened for hepatitis B e antigen
(HBeAg) in the serum using commercially available reagents from
Abbott Laboratories. HBeAg-positive progeny were screened for
homozygosity of the null mutation by PCR exactly as described
(10), and homozygosity of the H-2
 
d
 
 class I molecule (the restric-
tion element used by the hepatitis B surface antigen [HBsAg]-spe-
cific CTLs used in this study; see below) was screened by FACS
 
®
 
analysis as described (11). HBV transgenic mice that were ho-
mozygous for the H-2
 
d
 
 class I molecule and either homozygous
or heterozygous for the null mutation were matched for age (8–
10 wk), sex (male), and levels of HBeAg in their serum before ex-
perimental manipulations. All animals were housed in pathogen-
free rooms under strict barrier conditions.
 
Injection of HBsAg-specific CTLs.
 
 
 
A HBsAg-specific, H-2
 
d
 
 re-
stricted, CD8
 
1
 
 CTL line was derived from spleen cells of non-
transgenic B10.D2 mice immunized with 50 
 
m
 
g of plasmid
pCMV-S2/S as described (11). The CTL line was maintained by
weekly restimulation with irradiated P815 cells that stably express
the HBV large envelope protein (ayw subtype) containing HB-
sAg, as described previously (12). 5 d after the last stimulation, the
cells were washed, counted, suspended in HBSS containing 2%
FCS, and injected intravenously into HBV transgenic mice. 2 d
after injection, mice were killed, and their livers were harvested
for histological and histochemical analyses, or they were snap fro-
zen in liquid nitrogen and stored at 
 
2
 
80
 
8
 
C for subsequent molec-
ular analyses (see below).
 
LCMV Isolates and Infection of Mice.
 
 
 
Clone 2.2 of the WE
isolate of LCMV used in this study has been described previously
(4). Stocks of virus were prepared by growth on baby hamster
kidney cells. All virus stocks were free of mycoplasma contamina-
tion as determined by Hoechst staining of cells growing in antibi-
otic-free medium 48 h after virus infection. The titers of the
LCMV stocks, and also infectious virus titers in murine tissues,
were determined by plaque assay on Vero cells as described (4).
Adult male mice (8-10-wk old) were infected by single intrave-
nous inoculation (2 
 
3
 
 10
 
6
 
 PFU) of LCMV WE clone 2.2 per
mouse and killed either 24 h or 7 d after infection, when their
livers were processed exactly as described for the CTL-injected
animals.
 
Poly-I/C Treatment. 
 
Mice were injected intravenously with
a single dose (200 
 
m
 
g per mouse) of poly-I/C (Sigma Chemical
Co.) and killed 24 h later. Their livers were also processed exactly
as described for the CTL-injected animals.
 
Tissue DNA and RNA Analyses. 
 
Frozen liver tissue was me-
chanically pulverized under liquid nitrogen, and total genomic
DNA and RNA were isolated for Southern and Northern blot
analyses exactly as described previously (9). Nylon membranes
were analyzed for HBV DNA, HBV RNA, LCMV RNA, glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH), and 2
 
9
 
5
 
9
 
-oli-
goadenylate synthetase (2
 
9
 
5
 
9
 
-OAS) as described (4). Quantitation
of cytokine, T lymphocyte, and macrophage marker mRNAs
was performed by RNase protection assay exactly as described
previously (2). The iNOS probe (provided by Iain Campbell,
The Scripps Research Institute, La Jolla, CA) used in the RNase
protection has been described previously (13). The relative abun-
dance of specific DNA and RNA molecules was quantitated by
PhosphorImaging analysis using the Optiquant™ image analysis
software (Packard).
 
In Situ Hybridization.
 
 
 
This procedure was carried out exactly
as described (9). The 
 
33
 
P-labeled antisense RNA probe used in
this study was prepared by transcription from the T7 promoter of
a plasmid containing the full-length cDNA for iNOS (provided
by Iain Campbell) as described previously (13).
 
Biochemical and Histological Analyses. 
 
The extent of hepato-
cellular injury was monitored by measuring serum alanine ami-
notransferase (sALT) activity at multiple time points after treat-
ment with saline, CTLs, IFN-
 
a
 
, poly-I/C, or infection with
LCMV. sALT activity was measured in a Paramax™ chemical
analyzer (Baxter Diagnostics) exactly as described previously (9).
For histological analysis, liver tissue samples were fixed in 10%
zinc-buffered formalin (Anatech), embedded in paraffin, sec-
tioned (3 
 
m
 
m), and stained with hematoxylin and eosin exactly as
described elsewhere (9).
 
Results and Discussion
 
HBV Replicates at High Levels in the Liver of iNOS-deficient
Mice.
 
 
 
HBV transgenic mice from lineage 1.3.46 were
crossed with iNOS
 
2
 
/
 
2
 
 mice. Groups (six mice each) of
age- (8–10 wk), sex- (male), and serum HBeAg–matched
animals that were either heterozygous (
 
1
 
/
 
2
 
) or homozy-
gous (
 
2
 
/
 
2
 
) for the iNOS null mutation were killed, and
their livers were harvested. After extraction, total hepatic
RNA and DNA were pooled in each group and analyzed
for HBV gene expression and replication by Northern and
Southern blot analyses.
As shown in Fig. 1, iNOS
 
2
 
/
 
2
 
 mice replicate HBV in the
liver at levels that are almost twofold higher than the re-
spective heterozygous control littermates (as measured by
PhosphorImaging analysis; data not shown), whereas the
intrahepatic levels of HBV RNA, including the prege-
nomic 3.5-kb RNA, were very similar. Actually, the pre-
genomic RNA content was slightly lower (0.92-fold) in
iNOS
 
2
 
/
 
2
 
 mice. These results suggest that NO inhibits
HBV replication at a step(s) in the viral life cycle after pre-
genomic RNA accumulation. Although the differences are
relatively small (less than twofold), the higher content of
HBV replicative forms in the liver of iNOS
 
2
 
/
 
2
 
 mice sug-
gests that basal levels of NO may regulate HBV replication 
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to some degree in the uninflamed liver. Heterozygous and
homozygous iNOS-deficient mice have been monitored
histologically for over 1 yr without observing pathological
changes in any organ, especially the liver (not shown). Lack
of inflammation in these livers was also underscored by the
absence of sALT elevation (Fig. 1, bottom).
 
NO Mediates Most of the Antiviral Activity of IFN-
 
g
 
 Pro-
duced by HBsAg-specific CTLs.
 
We have shown previously
that the noncytopathic antiviral effect of CTLs is blocked
by a cocktail of antibodies to IFN-
 
g
 
 and TNF-
 
a
 
 (2). We
have also shown recently that the amount of IFN-
 
g 
 
pro-
duced by passively transferred CTLs is sufficient to inhibit
HBV replication in the liver of transgenic mice, indicating
that TNF-
 
a
 
 and other cytokines, including IFN-
 
a
 
/
 
b
 
, are
not required for the antiviral activity of CTLs (3). To mon-
itor the CTL-dependent antiviral activity in the liver of
iNOS
 
2
 
/
 
2
 
 mice, six age-, sex-, and serum HBeAg–matched
transgenic mice that were either heterozygous or homozy-
gous for the iNOS null mutation were injected intrave-
nously with 2.5 
 
3 
 
10
 
7
 
 lymphocytes derived from a CD8
 
1
 
HBsAg-specific CTL line. Mice were bled and killed, livers
were harvested 2 d later, and results were compared with
those observed in livers pooled from 10 age-, sex-, and se-
rum HBeAg–matched transgenic littermates injected with
saline (NaCl).
As shown in Fig. 2 for three representative mice per
group, iNOS mRNA was induced in the liver of iNOS
 
1
 
/
 
2
 
mice after CTL injection, and this was associated with a
profound inhibition of HBV DNA replicative forms. In
contrast, iNOS mRNA was not induced in the liver of
iNOS
 
2
 
/
 
2
 
 mice, and this was associated with persistence of
HBV DNA replicative forms (Fig. 2). The lack of inhibi-
tion of HBV replication in iNOS
 
2
 
/
 
2
 
 mice was not due to a
defect in the entry and/or activation of CTLs into the liver,
as CD8, CD3, IFN-
 
g
 
, and TNF-
 
a
 
 mRNA were induced
in the liver of these animals at levels that were even higher
than those observed in the liver of iNOS
 
1
 
/
 
2
 
 mice (Fig. 2).
As IFN-
 
g
 
 produced by transferred CTLs is sufficient to in-
hibit HBV replication (3), these results demonstrate that
NO mediates most of the antiviral activity of IFN-
 
g
 
 in our
system. To determine which cells produce NO in the
CTL-injected livers, the hepatic content of iNOS mRNA
was also analyzed by in situ hybridization analysis in wild-
type animals 2 d after CTL injection. As shown in Fig. 3,
most iNOS mRNA was detected in lymphomononuclear
inflammatory cells (arrowheads), indicating that they,
rather than hepatocytes, represent the major source of NO
in the CTL-injected livers. Along with the increased in-
flammatory infiltrate, the severity of liver disease (moni-
tored by sALT) was also significantly higher in iNOS
 
2
 
/
 
2
 
mice compared with heterozygous controls (Fig. 2, bot-
tom). These results suggest that NO may have inhibited the
severity of liver disease by inhibiting the recruitment of the
transferred CTLs into the liver, in keeping with reports
Figure 1. Hepatic HBV replication in
iNOS2/2 mice. Six age- (8–10 wk),
sex- (male), and serum HBeAg–
matched mice that were either heterozy-
gous (1/2) or homozygous (2/2) for
the indicated null mutation were killed,
and the livers were harvested. After ex-
traction, total hepatic RNA and DNA
were pooled in each group and analyzed
for HBV gene expression and replica-
tion by Northern (NB) and Southern
blot (SB) analyses. The membranes were
hybridized with 32P-labeled HBV- and
GAPDH-specific DNA probes. South-
ern blot analysis was performed with 30
mg of total hepatic DNA. All DNA
samples were RNase treated before gel
electrophoresis. Bands corresponding to
the integrated transgene, relaxed circular
(RC), and single-stranded (SS) linear
HBV DNA replicative forms are indi-
cated. The integrated transgene can be
used to normalize the amount of DNA
bound to the membrane. The filter was
hybridized with a 32P-labeled HBV-specific DNA probe. The mean
sALT activity, measured at the time of autopsy, is indicated (bottom) for
each group and is expressed in U/liter (U/l).
Figure 2. NO mediates most of the antiviral activity of IFN-g pro-
duced by HBsAg-specific CTLs. Age-, sex-, and serum HBeAg–matched
transgenic mice from the same groups of mice described in the legend to
Fig. 1 were injected intravenously with 2.5 3 107 CTLs and killed 2 d
later. Total hepatic RNA and DNA were analyzed for HBV gene expres-
sion and replication and for the message of 2959-OAS and GAPDH as de-
scribed in the legend to Fig. 1. Total hepatic RNA (10 mg) from the same
mice was also analyzed by RNase protection assay (RPA) for the expres-
sion of iNOS, IFN-g, and TNF-a transcripts and for the expression of
CD3, CD4, CD8, and F480, as indicated. The mRNA encoding the ri-
bosomal protein L32 was used to normalize the amount of RNA loaded
in each lane. Results were compared with those observed in livers pooled
from six age-, sex-, and serum HBeAg–matched transgenic saline controls
(NaCl). The mean sALT activity, measured at the time of autopsy, is in-
dicated (bottom) for each group and is expressed in U/liter (U/l). SB,
Southern blot; NB, Northern blot; RC, relaxed circular; SS, single
stranded.  
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that NO inhibits leukocyte adhesion to endothelial cells.
(14–16).
 
NO Does Not Mediate the Antiviral Activity of IFN-
 
a
 
/
 
b
Induced by Poly-I/C or LCMV Infection.  We have shown
previously that poly-I/C inhibits HBV replication by in-
ducing the production of IFN-a/b in the liver (3). To
monitor the antiviral activity of poly-I/C in the animals
described above, three age-, sex-, and serum HBeAg–
matched transgenic mice that were either heterozygous or
homozygous for the iNOS null mutation were injected in-
travenously with poly-I/C and killed 24 h after injection.
As shown in Fig. 4, a strong induction of 2959-OAS (a
known IFN-a/b–responsive gene) was observed in the
liver of iNOS1/2 and iNOS2/2 mice, and this coincided
with a profound inhibition of HBV replication in both
group of animals. Importantly, poly-I/C did not induce
iNOS mRNA in the iNOS1/2 controls in which HBV
replication was profoundly reduced (Fig. 4). Collectively,
these results demonstrate that NO does not mediate the an-
tiviral activity of IFN-a/b. No liver disease was observed
histologically (not shown) or biochemically (Fig. 4, bot-
tom) in poly-I/C–injected animals; accordingly, their livers
showed no induction of IFN-g, T cell, and macrophage
marker RNA (Fig. 4).
We have shown previously that HBV replication is also
inhibited by IFN-a/b induced in the liver during LCMV
infection (3, 4). In this study, we showed that the hepatic
induction of IFN-a/b on day 1 after LCMV infection co-
incided with a profound decrease in HBV replication in
iNOS2/2 mice (Fig. 5), reiterating that NO is not in-
volved in the IFN-a/b–dependent inhibition of HBV
replication. HBV replication was still abolished at day 7 af-
ter LCMV infection, when the hepatic induction of IFN-
a/b was substantially decreased, and IFN-g was strongly
induced (Fig. 5). The fact that HBV replication did not re-
appear in the liver of iNOS2/2 mice (in which NO medi-
ates most of the antiviral activity of IFN-g) is not surpris-
ing for the following reasons: (a) IFN-a/b is still strongly
induced between days 1 and 5 after acute LCMV infection
(4); (b) the reappearance of HBV replication after cessation
of intrahepatic cytokine induction is a relatively slow pro-
cess that takes about 1 wk (17); and (c) IFN-g or TNF-a,
both of which are strongly induced at this time point,
could trigger iNOS-independent antiviral events within
the hepatocyte.
LCMV Is also Susceptible to the Antiviral Effects of NO.
To determine the sensitivity of LCMV to NO, we moni-
tored the content of LCMV RNA in the liver of iNOS2/2
mice after an acute LCMV infection. No difference in the
hepatic content of LCMV RNA was observed between
iNOS2/2 and iNOS1/2 mice at day 1 after infection (Fig.
5, top), in keeping with the fact that iNOS mRNA was
not induced at this time point (Fig. 5). In contrast, IFN-
a/b (monitored by the increase in the message for 2959-
OAS) was strongly induced in the liver of both groups of
animals at this time point (Fig. 5). This indicates that NO
does not mediate the ability of IFN-a/b to inhibit LCMV
replication that we and others have reported previously (3,
18, 19).
Importantly, iNOS2/2 mice showed about fourfold
higher hepatic levels (calculated by PhosphorImaging anal-
ysis as mean values) of LCMV RNA on day 7 after infec-
tion, compared with iNOS1/2 control mice in which
iNOS mRNA was strongly induced (Fig. 5, top). Simi-
larly, higher levels of viral titers (analyzed by plaque assay,
Fig. 5) were detected in these animals. At this time point,
the LCMV-specific T cell response is known to be maxi-
mal in the liver (4), and as expected, CD8, CD4, CD3,
Figure 3. Intrahepatic distribution of
iNOS mRNA after adoptive transfer of
CTLs. Livers from two wild-type animals
(A, B and C, D) that were injected 2 d ear-
lier with CTLs were analyzed for the ex-
pression of iNOS mRNA by in situ hybrid-
ization using a specific 33P-labeled iNOS
riboprobe. Note that most iNOS RNA is
contained in lymphomononuclear inflam-
matory cells (arrowheads), whereas no
iNOS RNA is detectable in the hepatocytes
(hematoxylin and eosin; original magnifica-
tion: 3600). d. 2, day 2.1251 Guidotti et al. Brief Definitive Report
F480, IFN-g, and TNF-a mRNAs were strongly induced
in both groups of animals (Fig. 5). These results demon-
strate that LCMV is probably susceptible to the antiviral
effects of NO, like HBV. The fact that the iNOS-associ-
ated inhibition of LCMV replication observed on day 7
was associated with a strong intrahepatic induction of IFN-g
suggests that NO may have contributed to the known ca-
pacity of this cytokine to control LCMV replication (3, 20,
21). Despite similar content of cytokine, T cell, and mac-
rophage marker RNA, on day 7 after infection, there was a
relative high degree of variation in viral titers and LCMV
RNA in different individual iNOS1/2 mice. A similar de-
gree of variation in LCMV titer and RNA levels were
found in four additional iNOS1/2 mice from a different
experiment. The reason for this variability remains to be
determined.
In summary, this study shows that NO mediates the
ability of IFN-g, but not IFN-a/b, to inhibit HBV repli-
cation. The results also show that NO may also control
LCMV replication in the liver by an IFN-a/b–indepen-
dent mechanism that is probably triggered by IFN-g. Fi-
nally, we have shown that the absence of NO increases the
severity of liver disease observed after passive transfer of
HBV-specific CTLs or after infection with LCMV, sug-
gesting a protective role for this mediator. It is possible that
by inhibiting viral replication, NO may reduce the expres-
sion of viral antigens in the cell, thereby diminishing the
severity of the immune-mediated liver disease. Future re-
search intended to elucidate this protective mechanism as
well as the mechanisms responsible for the antiviral activity
of NO against HBV and LCMV is clearly warranted.
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Figure 4. NO does not mediate the antiviral activity of IFN-a/b in-
duced by poly-I/C. Age-, sex-, and serum HBeAg–matched transgenic
mice from the same groups of mice described in the legend to Fig. 1 were
killed 24 h after a single injection of poly-I/C (200 mg per mouse). Total
hepatic RNA and DNA were analyzed for HBV gene expression and
replication and for the message of iNOS, 2959-OAS, IFN-g, TNF-a, T
cell (CD8, CD4, CD3), and macrophage (F480) markers exactly as de-
scribed in the legends to Figs. 1 and 2. Results were compared with those
observed in livers of two age-, sex-, and serum HBeAg–matched litter-
mates that were injected with saline (NaCl). The mean sALT activity,
measured at the time of autopsy, is indicated (bottom) for each group and
is expressed in U/liter (U/l). SB, Southern blot; NB, Northern blot; RC,
relaxed circular; SS, single stranded; RPA, RNase protection assay.
Figure 5. Relative sensitivity of HBV and LCMV to the antiviral ef-
fects of NO. Age-, sex-, and serum HBeAg–matched transgenic mice
from the same groups of mice described in the legend to Fig. 1 were in-
fected with LCMV WE clone 2.2 (2 3 106 PFU per mouse) and killed
either 24 h or 7 d after infection. Total hepatic RNA and DNA were an-
alyzed for HBV gene expression and replication and for the message of
iNOS, 2959-OAS, IFN-g, TNF-a, T cell (CD8, CD4, CD3), and mac-
rophage (F480) markers exactly as described in the legend to Fig. 1.
Northern blot (NB) membranes were also hybridized with a 32P-labeled
LCMV-specific DNA probe (top). The results of the plaque assay (PFU/g)
of individual liver tissues are indicated for the day 7 time point. The PFU
results for the day 1 time point are expressed as mean values. Results were
compared with those observed in livers pooled from six age-, sex-, and
serum HBeAg–matched transgenic saline-injected controls (NaCl). The
mean sALT activity, measured at the time of autopsy, is indicated (bot-
tom) for each group and is expressed in U/liter (U/l). ND, not detect-
able; SB, Southern blot; RC, relaxed circular; SS, single stranded; RPA,
RNase protection assay.1252 NO-dependent Inhibition of HBV and LCMV Replication
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